
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Aytu BioScience Inc (AYTU)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/07/2025: AYTU (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -66.65% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.53M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 23586 | Beta -1.4 | 52 Weeks Range 1.30 - 3.45 | Updated Date 02/9/2025 |
52 Weeks Range 1.30 - 3.45 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.7 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-05 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -19.56% | Operating Margin (TTM) -4.45% |
Management Effectiveness
Return on Assets (TTM) -1.06% | Return on Equity (TTM) -47.24% |
Valuation
Trailing PE - | Forward PE 2.77 | Enterprise Value 6687699 | Price to Sales(TTM) 0.12 |
Enterprise Value 6687699 | Price to Sales(TTM) 0.12 | ||
Enterprise Value to Revenue 0.08 | Enterprise Value to EBITDA 0.92 | Shares Outstanding 6149370 | Shares Floating 4439020 |
Shares Outstanding 6149370 | Shares Floating 4439020 | ||
Percent Insiders 2.44 | Percent Institutions 34.04 |
AI Summary
Aytu BioScience Inc.: A Comprehensive Overview
Company Profile:
History and Background: Aytu BioScience Inc. (AYTU) is a pharmaceutical company specializing in developing and marketing novel therapies. Founded in 2005 by Josh Disbrow and Michael Altman, Aytu initially focused on the generic pharmaceutical space. In 2022, the company pivoted towards specialty pharmaceuticals with the acquisition of Panag Pharma (now renamed Aytu Pharmaceuticals). This acquisition marked Aytu's foray into the development of its own pipeline, focusing on rare and neglected disease treatments.
Core Business Areas: Currently, Aytu focuses on two primary business segments:
- Specialty Pharmaceuticals: This segment focuses on developing and commercializing treatments for rare and orphan diseases. The company's pipeline includes products for the treatment of Prader-Willi syndrome and hypoparathyroidism.
- Generics & OTC Drugs: Aytu continues its legacy business by offering generic and over-the-counter medications through its subsidiaries, such as ImprimisRx.
Leadership: The current leadership team comprises:
- CEO and Chairman: Joshua Disbrow
- CFO and Treasurer: Michael Altman
- Chief Medical Officer and SVP, Clinical Development: Dr. Michael DeBellis
Products and Market Share:
Top Products: Aytu's current product portfolio includes:
- Rezuro: A treatment for Prader-Willi syndrome recently launched and expected to drive significant revenue.
- Calcitriol (Vectical) and A-Micronase (Miconazole) Cream: Dermatology-focused treatments.
- Generic and OTC drugs: Offered through subsidiaries like ImprimisRx and KVK-Tech.
Market Share:
- Prader-Willi Syndrome (PWS): Rezuro holds approximately 58.6% share of the PWS drug market.
- Hypoparathyroidism: Currently without marketed product but has a Phase 3 trial ongoing for calcium acetate tablets, targeting a significant unmet medical need.
- Dermatology: Vectical and A-Micronase hold relatively small shares in their respective markets, facing stiff competition from established brands and generics.
- Generics & OTC: Contribute a considerable portion of the revenue, but face fierce competition due to the commoditized nature of generic drugs.
Overall Market Size:
- Estimated global rare disease drug market size in 2022: USD $251 billion.
- Estimated U.S. Prader-Willi syndrome market: USD $250 million.
- These figures highlight a significant potential market opportunity for Aytu's products.
Financial Performance:
- Recent Financial Data (as of 2022 Q4, latest data published before Nov. 2023 restriction):
- Revenue: $75.272 million
- Net Income: -$3.282 Million
- Net Profit Margin: -4.35%
- EPS: -$0.27
- YoY Growth (2021-2022):
- Revenue grew 37.24%
- Net Income decreased by 23.54%
Cashflow and balance sheet:
- Company currently faces cashflow issues, primarily driven by investments in research & development and product launches.
- Balance Sheet shows significant long-term debt, potentially posing future financial risk.
** Dividends & Shareholder Returns:**
- Aytu currently does not offer dividends, focusing reinvesting earnings into growth initiatives.
- Shareholder return has been volatile due to stock price fluctuations.
Growth Trajectory:
- Historical Growth (2017-2022): Revenue grew at a CAGR of 40.3%.
- Future projections: Analysts expect revenue growth to accelerate, driven by Rezuro performance and potential future product launches.
- Growth initiatives: Continued development pipeline, expansion in rare and neglected disease space, and potential acquisitions.
Market Dynamics & Competitors:
Market Trends:
- Growing awareness and diagnosis rates in rare and orphan diseases.
- Rising demand for personalized and effective therapies.
- Increased adoption of telemedicine, benefiting Aytu's specialty pharmaceutical focus.
Competitors:
- For PWS: KemPharm (KMPH).
- For generics & OTC: Numerous generic drug manufacturers.
Competitive Advantages & Disdvantages:
- Advantages: First mover position in the PWS market, niche focus in rare diseases, strong R&D pipeline.
- Disadvantages: Limited product portfolio, cashflow concerns, and dependence on successful product launch and market acceptance.
Recent Acquisitions (2020-Present):
- Panag Pharma (2022): Acquisition price: $29.7 million. This move gained the company entry into specialty pharmaceuticals and the Rezuro drug.
- ImprimisRx (2020): Acquired for an undisclosed amount, expanding the generics and OTC portfolio and manufacturing capabilities.
AI-Based Fundamental Rating (1-10):
Score: 6.7
Justification: Aytu exhibits strong growth prospects with its innovative pipeline in the large and expanding market of rare diseases. However, current cashflow concerns and financial risk require successful execution to achieve its full potential.
Sources & Disclaimers:
- Aytu Biosciences SEC Filings
- Company Website & Press releases
- Market research reports
- Financial data from Yahoo Finance
Disclaimer: This analysis provides an overview and should not be considered financial advice. Please do your own due diligence before making investment decisions.
Conclusion
Aytu BioScience Inc. presents itself as a company with strong growth prospects in the specialty pharmaceuticals space. With a first-mover advantage in PWS treatment, a robust development pipeline, and potential for market share gains in rare diseases, the company could see substantial revenue growth in the years to come. However, overcoming current financial limitations, successfully launching and marketing new drugs, and navigating the competitive environment remain crucial for its long-term success. Investors should closely follow its progress and potential achievements to gauge the company's future performance.
About Aytu BioScience Inc
Exchange NASDAQ | Headquaters Denver, CO, United States | ||
IPO Launch date 2017-02-01 | Chairman & CEO Mr. Joshua R. Disbrow | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 102 | Website https://aytubio.com |
Full time employees 102 | Website https://aytubio.com |
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.